nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP3A4—Pimecrolimus—atopic dermatitis	0.0685	0.121	CbGbCtD
Sitaxentan—CYP2C19—Loratadine—atopic dermatitis	0.0617	0.109	CbGbCtD
Sitaxentan—CYP2C19—Diphenhydramine—atopic dermatitis	0.0617	0.109	CbGbCtD
Sitaxentan—CYP2C9—Loratadine—atopic dermatitis	0.0513	0.0908	CbGbCtD
Sitaxentan—CYP2C9—Diphenhydramine—atopic dermatitis	0.0513	0.0908	CbGbCtD
Sitaxentan—CYP3A4—Tacrolimus—atopic dermatitis	0.0407	0.0721	CbGbCtD
Sitaxentan—CYP2C19—Prednisone—atopic dermatitis	0.0342	0.0605	CbGbCtD
Sitaxentan—CYP3A4—Loratadine—atopic dermatitis	0.0298	0.0528	CbGbCtD
Sitaxentan—CYP3A4—Methylprednisolone—atopic dermatitis	0.0273	0.0483	CbGbCtD
Sitaxentan—CYP2C19—Dexamethasone—atopic dermatitis	0.0213	0.0378	CbGbCtD
Sitaxentan—CYP3A4—Triamcinolone—atopic dermatitis	0.0207	0.0366	CbGbCtD
Sitaxentan—CYP2C9—Dexamethasone—atopic dermatitis	0.0177	0.0314	CbGbCtD
Sitaxentan—CYP3A4—Betamethasone—atopic dermatitis	0.0177	0.0314	CbGbCtD
Sitaxentan—CYP3A4—Prednisolone—atopic dermatitis	0.0175	0.031	CbGbCtD
Sitaxentan—CYP3A4—Hydrocortisone—atopic dermatitis	0.0166	0.0294	CbGbCtD
Sitaxentan—CYP3A4—Prednisone—atopic dermatitis	0.0165	0.0293	CbGbCtD
Sitaxentan—CYP3A4—Dexamethasone—atopic dermatitis	0.0103	0.0183	CbGbCtD
Sitaxentan—EDNRB—Peptide GPCRs—CCR3—atopic dermatitis	0.00197	0.0253	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL22—atopic dermatitis	0.00177	0.0227	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide GPCRs—CXCR3—atopic dermatitis	0.00172	0.0221	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL27—atopic dermatitis	0.00157	0.0202	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL17—atopic dermatitis	0.00141	0.0181	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—CCR3—atopic dermatitis	0.00141	0.0181	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL22—atopic dermatitis	0.00126	0.0162	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—CXCR3—atopic dermatitis	0.00123	0.0158	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL22—atopic dermatitis	0.00119	0.0152	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL11—atopic dermatitis	0.00114	0.0146	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL27—atopic dermatitis	0.00113	0.0145	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide GPCRs—CCR5—atopic dermatitis	0.00108	0.0139	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL27—atopic dermatitis	0.00106	0.0136	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—CXCR3—atopic dermatitis	0.00105	0.0134	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL17—atopic dermatitis	0.00101	0.013	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL17—atopic dermatitis	0.000947	0.0122	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCR3—atopic dermatitis	0.000928	0.0119	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL22—atopic dermatitis	0.000902	0.0116	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL22—atopic dermatitis	0.000848	0.0109	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—TAC1—atopic dermatitis	0.000838	0.0108	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—NPS—atopic dermatitis	0.000838	0.0108	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—TAC1—atopic dermatitis	0.000827	0.0106	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—NPS—atopic dermatitis	0.000827	0.0106	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL11—atopic dermatitis	0.000815	0.0105	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCR3—atopic dermatitis	0.000811	0.0104	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL27—atopic dermatitis	0.000804	0.0103	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—CCR5—atopic dermatitis	0.000774	0.00993	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL11—atopic dermatitis	0.000764	0.0098	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL27—atopic dermatitis	0.000756	0.0097	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—atopic dermatitis	0.000749	0.00962	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—atopic dermatitis	0.000749	0.00962	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CCR3—atopic dermatitis	0.000727	0.00933	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL17—atopic dermatitis	0.000721	0.00926	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL17—atopic dermatitis	0.000678	0.0087	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCR3—atopic dermatitis	0.000664	0.00853	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Other—CCR5—atopic dermatitis	0.000656	0.00842	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCL10—atopic dermatitis	0.000656	0.00842	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—MAPK8—atopic dermatitis	0.000654	0.0084	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCL22—atopic dermatitis	0.000646	0.00829	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CXCR3—atopic dermatitis	0.000635	0.00815	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCR3—atopic dermatitis	0.000623	0.00799	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—NPS—atopic dermatitis	0.0006	0.0077	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—TAC1—atopic dermatitis	0.0006	0.0077	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—NPS—atopic dermatitis	0.000592	0.0076	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—TAC1—atopic dermatitis	0.000592	0.0076	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL11—atopic dermatitis	0.000582	0.00746	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCR3—atopic dermatitis	0.000581	0.00745	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCL27—atopic dermatitis	0.000576	0.00739	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCL5—atopic dermatitis	0.000564	0.00725	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	0.000555	0.00712	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	0.000555	0.00712	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL11—atopic dermatitis	0.000547	0.00702	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	0.000544	0.00698	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—atopic dermatitis	0.000536	0.00688	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—atopic dermatitis	0.000536	0.00688	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR3—atopic dermatitis	0.00052	0.00668	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCL17—atopic dermatitis	0.000516	0.00663	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CCR5—atopic dermatitis	0.000509	0.00653	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCR3—atopic dermatitis	0.000474	0.00609	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCL10—atopic dermatitis	0.000469	0.00602	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—MAPK8—atopic dermatitis	0.000468	0.00601	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL22—atopic dermatitis	0.000463	0.00594	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCL27—atopic dermatitis	0.000455	0.00583	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CXCR3—atopic dermatitis	0.000455	0.00583	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR3—atopic dermatitis	0.000446	0.00572	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	0.00044	0.00565	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—TAC1—atopic dermatitis	0.000423	0.00542	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—NPS—atopic dermatitis	0.000423	0.00542	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCL11—atopic dermatitis	0.000416	0.00534	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCR3—atopic dermatitis	0.000414	0.00532	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL27—atopic dermatitis	0.000413	0.0053	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCL5—atopic dermatitis	0.000404	0.00519	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	0.000398	0.00511	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	0.000397	0.0051	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	0.000397	0.0051	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	0.000389	0.005	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	0.000379	0.00486	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL17—atopic dermatitis	0.00037	0.00475	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CCR5—atopic dermatitis	0.000364	0.00467	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	0.000341	0.00438	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCR3—atopic dermatitis	0.000339	0.00436	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL10—atopic dermatitis	0.000335	0.0043	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCL22—atopic dermatitis	0.000331	0.00425	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CCL27—atopic dermatitis	0.000325	0.00418	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	0.000315	0.00404	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCL8—atopic dermatitis	0.000307	0.00395	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—TAC1—atopic dermatitis	0.000302	0.00388	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—NPS—atopic dermatitis	0.000302	0.00388	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL11—atopic dermatitis	0.000298	0.00383	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atopic dermatitis	0.000297	0.00382	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCR3—atopic dermatitis	0.000297	0.00381	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCL27—atopic dermatitis	0.000295	0.00379	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FCER2—atopic dermatitis	0.000294	0.00378	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCL5—atopic dermatitis	0.000288	0.0037	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	0.000285	0.00366	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCL22—atopic dermatitis	0.000274	0.00351	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	0.000271	0.00348	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCR3—atopic dermatitis	0.000268	0.00344	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCL17—atopic dermatitis	0.000265	0.0034	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CCR5—atopic dermatitis	0.00026	0.00333	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	0.000244	0.00313	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCL27—atopic dermatitis	0.000244	0.00313	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCR3—atopic dermatitis	0.000243	0.00312	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL10—atopic dermatitis	0.00024	0.00308	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—TAC1—atopic dermatitis	0.000239	0.00307	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—NPS—atopic dermatitis	0.000239	0.00307	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCR3—atopic dermatitis	0.000234	0.00301	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—IL5—atopic dermatitis	0.000222	0.00285	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCL8—atopic dermatitis	0.00022	0.00282	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCL17—atopic dermatitis	0.000219	0.00281	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—NPS—atopic dermatitis	0.000217	0.00278	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—TAC1—atopic dermatitis	0.000217	0.00278	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCL11—atopic dermatitis	0.000214	0.00274	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCR3—atopic dermatitis	0.000213	0.00273	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FCER2—atopic dermatitis	0.000211	0.0027	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCL5—atopic dermatitis	0.000206	0.00265	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	0.000206	0.00265	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL5—atopic dermatitis	0.000202	0.00259	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atopic dermatitis	0.000196	0.00252	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCL22—atopic dermatitis	0.000196	0.00251	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KIF3A—atopic dermatitis	0.000195	0.0025	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CCR3—atopic dermatitis	0.000192	0.00246	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL10—atopic dermatitis	0.000189	0.00243	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CCR5—atopic dermatitis	0.000186	0.00239	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCL11—atopic dermatitis	0.000176	0.00226	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CMA1—atopic dermatitis	0.000176	0.00226	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCL27—atopic dermatitis	0.000175	0.00224	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CCR3—atopic dermatitis	0.000174	0.00224	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL10—atopic dermatitis	0.000172	0.00221	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—TAC1—atopic dermatitis	0.000171	0.00219	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—NPS—atopic dermatitis	0.000171	0.00219	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCR3—atopic dermatitis	0.000168	0.00215	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT6—atopic dermatitis	0.000166	0.00213	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCL5—atopic dermatitis	0.000163	0.00209	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—IL5—atopic dermatitis	0.000159	0.00204	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL8—atopic dermatitis	0.000157	0.00202	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCL17—atopic dermatitis	0.000157	0.00201	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atopic dermatitis	0.000156	0.00201	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—TAC1—atopic dermatitis	0.000155	0.00199	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—NPS—atopic dermatitis	0.000155	0.00199	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCR3—atopic dermatitis	0.000152	0.00195	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCL5—atopic dermatitis	0.000148	0.0019	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	0.000148	0.00189	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CCR5—atopic dermatitis	0.000147	0.00188	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL5—atopic dermatitis	0.000144	0.00185	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCR3—atopic dermatitis	0.000144	0.00184	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KIF3A—atopic dermatitis	0.00014	0.00179	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL10—atopic dermatitis	0.000135	0.00174	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CCR5—atopic dermatitis	0.000133	0.00171	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NPS—atopic dermatitis	0.000128	0.00164	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TAC1—atopic dermatitis	0.000128	0.00164	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CMA1—atopic dermatitis	0.000126	0.00162	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCL11—atopic dermatitis	0.000126	0.00162	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCR3—atopic dermatitis	0.000126	0.00161	CbGpPWpGaD
Sitaxentan—Dermatitis—Fluocinolone Acetonide—atopic dermatitis	0.000123	0.000345	CcSEcCtD
Sitaxentan—Rhinitis—Triamcinolone—atopic dermatitis	0.000123	0.000345	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL10—atopic dermatitis	0.000123	0.00158	CbGpPWpGaD
Sitaxentan—Rhinitis—Methylprednisolone—atopic dermatitis	0.000123	0.000344	CcSEcCtD
Sitaxentan—Haemorrhage—Triamcinolone—atopic dermatitis	0.000123	0.000344	CcSEcCtD
Sitaxentan—Haemorrhage—Methylprednisolone—atopic dermatitis	0.000122	0.000343	CcSEcCtD
Sitaxentan—Headache—Fluocinolone Acetonide—atopic dermatitis	0.000122	0.000343	CcSEcCtD
Sitaxentan—Feeling abnormal—Tacrolimus—atopic dermatitis	0.000122	0.000343	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Betamethasone—atopic dermatitis	0.000122	0.000342	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Dexamethasone—atopic dermatitis	0.000122	0.000342	CcSEcCtD
Sitaxentan—Eye disorder—Hydrocortisone—atopic dermatitis	0.000122	0.000341	CcSEcCtD
Sitaxentan—Myocardial infarction—Dexamethasone—atopic dermatitis	0.000122	0.00034	CcSEcCtD
Sitaxentan—Myocardial infarction—Betamethasone—atopic dermatitis	0.000122	0.00034	CcSEcCtD
Sitaxentan—Conjunctivitis—Betamethasone—atopic dermatitis	0.000121	0.000338	CcSEcCtD
Sitaxentan—Conjunctivitis—Dexamethasone—atopic dermatitis	0.000121	0.000338	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—IL5—atopic dermatitis	0.000119	0.00153	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT6—atopic dermatitis	0.000119	0.00152	CbGpPWpGaD
Sitaxentan—Vomiting—Mometasone—atopic dermatitis	0.000119	0.000332	CcSEcCtD
Sitaxentan—Visual impairment—Methylprednisolone—atopic dermatitis	0.000118	0.00033	CcSEcCtD
Sitaxentan—Urticaria—Tacrolimus—atopic dermatitis	0.000118	0.00033	CcSEcCtD
Sitaxentan—Immune system disorder—Hydrocortisone—atopic dermatitis	0.000118	0.00033	CcSEcCtD
Sitaxentan—Rash—Mometasone—atopic dermatitis	0.000118	0.000329	CcSEcCtD
Sitaxentan—Dermatitis—Mometasone—atopic dermatitis	0.000118	0.000329	CcSEcCtD
Sitaxentan—Body temperature increased—Tacrolimus—atopic dermatitis	0.000117	0.000329	CcSEcCtD
Sitaxentan—Headache—Mometasone—atopic dermatitis	0.000117	0.000327	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CCL5—atopic dermatitis	0.000117	0.0015	CbGpPWpGaD
Sitaxentan—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.000116	0.000325	CcSEcCtD
Sitaxentan—Eye disorder—Methylprednisolone—atopic dermatitis	0.000114	0.00032	CcSEcCtD
Sitaxentan—Mental disorder—Hydrocortisone—atopic dermatitis	0.000114	0.00032	CcSEcCtD
Sitaxentan—Cardiac disorder—Methylprednisolone—atopic dermatitis	0.000114	0.000318	CcSEcCtD
Sitaxentan—Malnutrition—Hydrocortisone—atopic dermatitis	0.000113	0.000318	CcSEcCtD
Sitaxentan—Bradycardia—Betamethasone—atopic dermatitis	0.000113	0.000317	CcSEcCtD
Sitaxentan—Bradycardia—Dexamethasone—atopic dermatitis	0.000113	0.000317	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL8—atopic dermatitis	0.000112	0.00144	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atopic dermatitis	0.000112	0.00144	CbGpPWpGaD
Sitaxentan—Haemoglobin—Dexamethasone—atopic dermatitis	0.000112	0.000313	CcSEcCtD
Sitaxentan—Haemoglobin—Betamethasone—atopic dermatitis	0.000112	0.000313	CcSEcCtD
Sitaxentan—Haemorrhage—Betamethasone—atopic dermatitis	0.000111	0.000312	CcSEcCtD
Sitaxentan—Haemorrhage—Dexamethasone—atopic dermatitis	0.000111	0.000312	CcSEcCtD
Sitaxentan—Angiopathy—Methylprednisolone—atopic dermatitis	0.000111	0.000311	CcSEcCtD
Sitaxentan—Nausea—Mometasone—atopic dermatitis	0.000111	0.00031	CcSEcCtD
Sitaxentan—Immune system disorder—Methylprednisolone—atopic dermatitis	0.000111	0.00031	CcSEcCtD
Sitaxentan—Mediastinal disorder—Methylprednisolone—atopic dermatitis	0.00011	0.000309	CcSEcCtD
Sitaxentan—Weight decreased—Prednisone—atopic dermatitis	0.00011	0.000307	CcSEcCtD
Sitaxentan—Hypersensitivity—Tacrolimus—atopic dermatitis	0.000109	0.000306	CcSEcCtD
Sitaxentan—Hyperglycaemia—Prednisone—atopic dermatitis	0.000109	0.000306	CcSEcCtD
Sitaxentan—Ill-defined disorder—Prednisolone—atopic dermatitis	0.000108	0.000302	CcSEcCtD
Sitaxentan—Visual impairment—Betamethasone—atopic dermatitis	0.000107	0.0003	CcSEcCtD
Sitaxentan—Visual impairment—Dexamethasone—atopic dermatitis	0.000107	0.0003	CcSEcCtD
Sitaxentan—Mental disorder—Methylprednisolone—atopic dermatitis	0.000107	0.0003	CcSEcCtD
Sitaxentan—Malnutrition—Methylprednisolone—atopic dermatitis	0.000107	0.000298	CcSEcCtD
Sitaxentan—Asthenia—Tacrolimus—atopic dermatitis	0.000107	0.000298	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Prednisone—atopic dermatitis	0.000107	0.000298	CcSEcCtD
Sitaxentan—Myocardial infarction—Prednisone—atopic dermatitis	0.000106	0.000296	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CCL5—atopic dermatitis	0.000106	0.00136	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	0.000105	0.00135	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Hydrocortisone—atopic dermatitis	0.000105	0.000295	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CCR5—atopic dermatitis	0.000105	0.00135	CbGpPWpGaD
Sitaxentan—Malaise—Prednisolone—atopic dermatitis	0.000105	0.000293	CcSEcCtD
Sitaxentan—Vertigo—Prednisolone—atopic dermatitis	0.000104	0.000292	CcSEcCtD
Sitaxentan—Eye disorder—Dexamethasone—atopic dermatitis	0.000104	0.000291	CcSEcCtD
Sitaxentan—Eye disorder—Betamethasone—atopic dermatitis	0.000104	0.000291	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCR3—atopic dermatitis	0.000103	0.00132	CbGpPWpGaD
Sitaxentan—Malaise—Hydrocortisone—atopic dermatitis	0.000102	0.000286	CcSEcCtD
Sitaxentan—Vertigo—Hydrocortisone—atopic dermatitis	0.000102	0.000285	CcSEcCtD
Sitaxentan—Diarrhoea—Tacrolimus—atopic dermatitis	0.000102	0.000284	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CXCL10—atopic dermatitis	0.000102	0.0013	CbGpPWpGaD
Sitaxentan—Angiopathy—Dexamethasone—atopic dermatitis	0.000101	0.000283	CcSEcCtD
Sitaxentan—Angiopathy—Betamethasone—atopic dermatitis	0.000101	0.000283	CcSEcCtD
Sitaxentan—Ill-defined disorder—Triamcinolone—atopic dermatitis	9.92e-05	0.000278	CcSEcCtD
Sitaxentan—Ill-defined disorder—Methylprednisolone—atopic dermatitis	9.89e-05	0.000277	CcSEcCtD
Sitaxentan—Bradycardia—Prednisone—atopic dermatitis	9.88e-05	0.000276	CcSEcCtD
Sitaxentan—Alopecia—Dexamethasone—atopic dermatitis	9.84e-05	0.000276	CcSEcCtD
Sitaxentan—Alopecia—Betamethasone—atopic dermatitis	9.84e-05	0.000276	CcSEcCtD
Sitaxentan—Dizziness—Tacrolimus—atopic dermatitis	9.82e-05	0.000275	CcSEcCtD
Sitaxentan—Discomfort—Prednisolone—atopic dermatitis	9.78e-05	0.000274	CcSEcCtD
Sitaxentan—Haemoglobin—Prednisone—atopic dermatitis	9.75e-05	0.000273	CcSEcCtD
Sitaxentan—Haemorrhage—Prednisone—atopic dermatitis	9.7e-05	0.000272	CcSEcCtD
Sitaxentan—Malaise—Triamcinolone—atopic dermatitis	9.64e-05	0.00027	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	9.62e-05	0.00123	CbGpPWpGaD
Sitaxentan—Malaise—Methylprednisolone—atopic dermatitis	9.62e-05	0.000269	CcSEcCtD
Sitaxentan—Vertigo—Triamcinolone—atopic dermatitis	9.6e-05	0.000269	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	9.6e-05	0.000269	CcSEcCtD
Sitaxentan—Vertigo—Methylprednisolone—atopic dermatitis	9.58e-05	0.000268	CcSEcCtD
Sitaxentan—Discomfort—Hydrocortisone—atopic dermatitis	9.55e-05	0.000267	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CCR5—atopic dermatitis	9.54e-05	0.00122	CbGpPWpGaD
Sitaxentan—Oedema—Prednisolone—atopic dermatitis	9.48e-05	0.000265	CcSEcCtD
Sitaxentan—Vomiting—Tacrolimus—atopic dermatitis	9.44e-05	0.000264	CcSEcCtD
Sitaxentan—Rash—Tacrolimus—atopic dermatitis	9.36e-05	0.000262	CcSEcCtD
Sitaxentan—Dermatitis—Tacrolimus—atopic dermatitis	9.35e-05	0.000262	CcSEcCtD
Sitaxentan—Headache—Tacrolimus—atopic dermatitis	9.3e-05	0.00026	CcSEcCtD
Sitaxentan—Oedema—Hydrocortisone—atopic dermatitis	9.26e-05	0.000259	CcSEcCtD
Sitaxentan—Tachycardia—Prednisolone—atopic dermatitis	9.26e-05	0.000259	CcSEcCtD
Sitaxentan—Infection—Hydrocortisone—atopic dermatitis	9.2e-05	0.000258	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—TAC1—atopic dermatitis	9.17e-05	0.00118	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NPS—atopic dermatitis	9.17e-05	0.00118	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Hydrocortisone—atopic dermatitis	9.08e-05	0.000254	CcSEcCtD
Sitaxentan—Eye disorder—Prednisone—atopic dermatitis	9.07e-05	0.000254	CcSEcCtD
Sitaxentan—Tachycardia—Hydrocortisone—atopic dermatitis	9.04e-05	0.000253	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	9.02e-05	0.000252	CcSEcCtD
Sitaxentan—Flushing—Prednisone—atopic dermatitis	9e-05	0.000252	CcSEcCtD
Sitaxentan—Skin disorder—Hydrocortisone—atopic dermatitis	9e-05	0.000252	CcSEcCtD
Sitaxentan—Ill-defined disorder—Dexamethasone—atopic dermatitis	9e-05	0.000252	CcSEcCtD
Sitaxentan—Ill-defined disorder—Betamethasone—atopic dermatitis	9e-05	0.000252	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CXCR3—atopic dermatitis	8.99e-05	0.00115	CbGpPWpGaD
Sitaxentan—Discomfort—Triamcinolone—atopic dermatitis	8.99e-05	0.000252	CcSEcCtD
Sitaxentan—Discomfort—Methylprednisolone—atopic dermatitis	8.97e-05	0.000251	CcSEcCtD
Sitaxentan—Dry mouth—Triamcinolone—atopic dermatitis	8.9e-05	0.000249	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL8—atopic dermatitis	8.87e-05	0.00114	CbGpPWpGaD
Sitaxentan—Anorexia—Hydrocortisone—atopic dermatitis	8.83e-05	0.000247	CcSEcCtD
Sitaxentan—Nausea—Tacrolimus—atopic dermatitis	8.82e-05	0.000247	CcSEcCtD
Sitaxentan—Angiopathy—Prednisone—atopic dermatitis	8.8e-05	0.000246	CcSEcCtD
Sitaxentan—Confusional state—Methylprednisolone—atopic dermatitis	8.77e-05	0.000246	CcSEcCtD
Sitaxentan—Immune system disorder—Prednisone—atopic dermatitis	8.76e-05	0.000245	CcSEcCtD
Sitaxentan—Malaise—Dexamethasone—atopic dermatitis	8.74e-05	0.000245	CcSEcCtD
Sitaxentan—Malaise—Betamethasone—atopic dermatitis	8.74e-05	0.000245	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CCL5—atopic dermatitis	8.74e-05	0.00112	CbGpPWpGaD
Sitaxentan—Oedema—Triamcinolone—atopic dermatitis	8.72e-05	0.000244	CcSEcCtD
Sitaxentan—Vertigo—Betamethasone—atopic dermatitis	8.71e-05	0.000244	CcSEcCtD
Sitaxentan—Vertigo—Dexamethasone—atopic dermatitis	8.71e-05	0.000244	CcSEcCtD
Sitaxentan—Infection—Triamcinolone—atopic dermatitis	8.67e-05	0.000243	CcSEcCtD
Sitaxentan—Hypotension—Hydrocortisone—atopic dermatitis	8.66e-05	0.000242	CcSEcCtD
Sitaxentan—Infection—Methylprednisolone—atopic dermatitis	8.65e-05	0.000242	CcSEcCtD
Sitaxentan—Insomnia—Prednisolone—atopic dermatitis	8.58e-05	0.00024	CcSEcCtD
Sitaxentan—Alopecia—Prednisone—atopic dermatitis	8.57e-05	0.00024	CcSEcCtD
Sitaxentan—Nervous system disorder—Methylprednisolone—atopic dermatitis	8.53e-05	0.000239	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—IL5—atopic dermatitis	8.52e-05	0.00109	CbGpPWpGaD
Sitaxentan—Tachycardia—Triamcinolone—atopic dermatitis	8.51e-05	0.000238	CcSEcCtD
Sitaxentan—Mental disorder—Prednisone—atopic dermatitis	8.5e-05	0.000238	CcSEcCtD
Sitaxentan—Tachycardia—Methylprednisolone—atopic dermatitis	8.49e-05	0.000238	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—IL2—atopic dermatitis	8.48e-05	0.00109	CbGpPWpGaD
Sitaxentan—Skin disorder—Methylprednisolone—atopic dermatitis	8.45e-05	0.000237	CcSEcCtD
Sitaxentan—Malnutrition—Prednisone—atopic dermatitis	8.44e-05	0.000236	CcSEcCtD
Sitaxentan—Insomnia—Hydrocortisone—atopic dermatitis	8.38e-05	0.000235	CcSEcCtD
Sitaxentan—Discomfort—Betamethasone—atopic dermatitis	8.16e-05	0.000228	CcSEcCtD
Sitaxentan—Discomfort—Dexamethasone—atopic dermatitis	8.16e-05	0.000228	CcSEcCtD
Sitaxentan—Dyspepsia—Hydrocortisone—atopic dermatitis	8.15e-05	0.000228	CcSEcCtD
Sitaxentan—Hypotension—Methylprednisolone—atopic dermatitis	8.13e-05	0.000228	CcSEcCtD
Sitaxentan—Pain—Prednisolone—atopic dermatitis	8.11e-05	0.000227	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NGF—atopic dermatitis	8.09e-05	0.00104	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL8—atopic dermatitis	8.06e-05	0.00103	CbGpPWpGaD
Sitaxentan—Decreased appetite—Hydrocortisone—atopic dermatitis	8.05e-05	0.000225	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	8e-05	0.000224	CcSEcCtD
Sitaxentan—Fatigue—Hydrocortisone—atopic dermatitis	7.99e-05	0.000224	CcSEcCtD
Sitaxentan—Pain—Hydrocortisone—atopic dermatitis	7.92e-05	0.000222	CcSEcCtD
Sitaxentan—Oedema—Betamethasone—atopic dermatitis	7.91e-05	0.000222	CcSEcCtD
Sitaxentan—Oedema—Dexamethasone—atopic dermatitis	7.91e-05	0.000222	CcSEcCtD
Sitaxentan—Insomnia—Triamcinolone—atopic dermatitis	7.89e-05	0.000221	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CCR5—atopic dermatitis	7.87e-05	0.00101	CbGpPWpGaD
Sitaxentan—Insomnia—Methylprednisolone—atopic dermatitis	7.87e-05	0.00022	CcSEcCtD
Sitaxentan—Infection—Betamethasone—atopic dermatitis	7.86e-05	0.00022	CcSEcCtD
Sitaxentan—Infection—Dexamethasone—atopic dermatitis	7.86e-05	0.00022	CcSEcCtD
Sitaxentan—Ill-defined disorder—Prednisone—atopic dermatitis	7.84e-05	0.000219	CcSEcCtD
Sitaxentan—Feeling abnormal—Prednisolone—atopic dermatitis	7.82e-05	0.000219	CcSEcCtD
Sitaxentan—Anaemia—Prednisone—atopic dermatitis	7.81e-05	0.000218	CcSEcCtD
Sitaxentan—Nervous system disorder—Betamethasone—atopic dermatitis	7.76e-05	0.000217	CcSEcCtD
Sitaxentan—Nervous system disorder—Dexamethasone—atopic dermatitis	7.76e-05	0.000217	CcSEcCtD
Sitaxentan—Agitation—Prednisone—atopic dermatitis	7.76e-05	0.000217	CcSEcCtD
Sitaxentan—Thrombocytopenia—Dexamethasone—atopic dermatitis	7.75e-05	0.000217	CcSEcCtD
Sitaxentan—Thrombocytopenia—Betamethasone—atopic dermatitis	7.75e-05	0.000217	CcSEcCtD
Sitaxentan—Tachycardia—Dexamethasone—atopic dermatitis	7.72e-05	0.000216	CcSEcCtD
Sitaxentan—Tachycardia—Betamethasone—atopic dermatitis	7.72e-05	0.000216	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—IL2—atopic dermatitis	7.7e-05	0.000989	CbGpPWpGaD
Sitaxentan—Dyspepsia—Triamcinolone—atopic dermatitis	7.68e-05	0.000215	CcSEcCtD
Sitaxentan—Dyspepsia—Methylprednisolone—atopic dermatitis	7.66e-05	0.000214	CcSEcCtD
Sitaxentan—Feeling abnormal—Hydrocortisone—atopic dermatitis	7.63e-05	0.000214	CcSEcCtD
Sitaxentan—Malaise—Prednisone—atopic dermatitis	7.62e-05	0.000213	CcSEcCtD
Sitaxentan—Vertigo—Prednisone—atopic dermatitis	7.59e-05	0.000212	CcSEcCtD
Sitaxentan—Anorexia—Dexamethasone—atopic dermatitis	7.54e-05	0.000211	CcSEcCtD
Sitaxentan—Anorexia—Betamethasone—atopic dermatitis	7.54e-05	0.000211	CcSEcCtD
Sitaxentan—Urticaria—Prednisolone—atopic dermatitis	7.53e-05	0.000211	CcSEcCtD
Sitaxentan—Fatigue—Triamcinolone—atopic dermatitis	7.52e-05	0.00021	CcSEcCtD
Sitaxentan—Fatigue—Methylprednisolone—atopic dermatitis	7.5e-05	0.00021	CcSEcCtD
Sitaxentan—Pain—Triamcinolone—atopic dermatitis	7.46e-05	0.000209	CcSEcCtD
Sitaxentan—Hypotension—Betamethasone—atopic dermatitis	7.4e-05	0.000207	CcSEcCtD
Sitaxentan—Hypotension—Dexamethasone—atopic dermatitis	7.4e-05	0.000207	CcSEcCtD
Sitaxentan—Urticaria—Hydrocortisone—atopic dermatitis	7.36e-05	0.000206	CcSEcCtD
Sitaxentan—Body temperature increased—Hydrocortisone—atopic dermatitis	7.32e-05	0.000205	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CXCL10—atopic dermatitis	7.27e-05	0.000933	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Triamcinolone—atopic dermatitis	7.19e-05	0.000201	CcSEcCtD
Sitaxentan—Feeling abnormal—Methylprednisolone—atopic dermatitis	7.17e-05	0.000201	CcSEcCtD
Sitaxentan—Insomnia—Betamethasone—atopic dermatitis	7.16e-05	0.0002	CcSEcCtD
Sitaxentan—Insomnia—Dexamethasone—atopic dermatitis	7.16e-05	0.0002	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	7.14e-05	0.0002	CcSEcCtD
Sitaxentan—Discomfort—Prednisone—atopic dermatitis	7.1e-05	0.000199	CcSEcCtD
Sitaxentan—Hypersensitivity—Prednisolone—atopic dermatitis	6.99e-05	0.000196	CcSEcCtD
Sitaxentan—Dyspepsia—Dexamethasone—atopic dermatitis	6.97e-05	0.000195	CcSEcCtD
Sitaxentan—Dyspepsia—Betamethasone—atopic dermatitis	6.97e-05	0.000195	CcSEcCtD
Sitaxentan—Urticaria—Triamcinolone—atopic dermatitis	6.93e-05	0.000194	CcSEcCtD
Sitaxentan—Urticaria—Methylprednisolone—atopic dermatitis	6.91e-05	0.000194	CcSEcCtD
Sitaxentan—Body temperature increased—Triamcinolone—atopic dermatitis	6.89e-05	0.000193	CcSEcCtD
Sitaxentan—Oedema—Prednisone—atopic dermatitis	6.89e-05	0.000193	CcSEcCtD
Sitaxentan—Decreased appetite—Dexamethasone—atopic dermatitis	6.88e-05	0.000193	CcSEcCtD
Sitaxentan—Decreased appetite—Betamethasone—atopic dermatitis	6.88e-05	0.000193	CcSEcCtD
Sitaxentan—Infection—Prednisone—atopic dermatitis	6.85e-05	0.000192	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Betamethasone—atopic dermatitis	6.83e-05	0.000191	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	6.83e-05	0.000191	CcSEcCtD
Sitaxentan—Hypersensitivity—Hydrocortisone—atopic dermatitis	6.82e-05	0.000191	CcSEcCtD
Sitaxentan—Fatigue—Dexamethasone—atopic dermatitis	6.82e-05	0.000191	CcSEcCtD
Sitaxentan—Fatigue—Betamethasone—atopic dermatitis	6.82e-05	0.000191	CcSEcCtD
Sitaxentan—Pain—Dexamethasone—atopic dermatitis	6.77e-05	0.000189	CcSEcCtD
Sitaxentan—Pain—Betamethasone—atopic dermatitis	6.77e-05	0.000189	CcSEcCtD
Sitaxentan—Nervous system disorder—Prednisone—atopic dermatitis	6.76e-05	0.000189	CcSEcCtD
Sitaxentan—Tachycardia—Prednisone—atopic dermatitis	6.73e-05	0.000188	CcSEcCtD
Sitaxentan—Skin disorder—Prednisone—atopic dermatitis	6.69e-05	0.000187	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NFKBIA—atopic dermatitis	6.68e-05	0.000857	CbGpPWpGaD
Sitaxentan—Asthenia—Hydrocortisone—atopic dermatitis	6.65e-05	0.000186	CcSEcCtD
Sitaxentan—Anorexia—Prednisone—atopic dermatitis	6.57e-05	0.000184	CcSEcCtD
Sitaxentan—Feeling abnormal—Betamethasone—atopic dermatitis	6.52e-05	0.000183	CcSEcCtD
Sitaxentan—Feeling abnormal—Dexamethasone—atopic dermatitis	6.52e-05	0.000183	CcSEcCtD
Sitaxentan—Hypersensitivity—Triamcinolone—atopic dermatitis	6.43e-05	0.00018	CcSEcCtD
Sitaxentan—Hypersensitivity—Methylprednisolone—atopic dermatitis	6.41e-05	0.000179	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL8—atopic dermatitis	6.35e-05	0.000815	CbGpPWpGaD
Sitaxentan—Diarrhoea—Hydrocortisone—atopic dermatitis	6.34e-05	0.000177	CcSEcCtD
Sitaxentan—Urticaria—Dexamethasone—atopic dermatitis	6.29e-05	0.000176	CcSEcCtD
Sitaxentan—Urticaria—Betamethasone—atopic dermatitis	6.29e-05	0.000176	CcSEcCtD
Sitaxentan—Dizziness—Prednisolone—atopic dermatitis	6.27e-05	0.000176	CcSEcCtD
Sitaxentan—Asthenia—Triamcinolone—atopic dermatitis	6.26e-05	0.000175	CcSEcCtD
Sitaxentan—Body temperature increased—Dexamethasone—atopic dermatitis	6.26e-05	0.000175	CcSEcCtD
Sitaxentan—Body temperature increased—Betamethasone—atopic dermatitis	6.26e-05	0.000175	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCL5—atopic dermatitis	6.26e-05	0.000803	CbGpPWpGaD
Sitaxentan—Asthenia—Methylprednisolone—atopic dermatitis	6.24e-05	0.000175	CcSEcCtD
Sitaxentan—Insomnia—Prednisone—atopic dermatitis	6.23e-05	0.000174	CcSEcCtD
Sitaxentan—Dizziness—Hydrocortisone—atopic dermatitis	6.13e-05	0.000171	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2—atopic dermatitis	6.07e-05	0.000779	CbGpPWpGaD
Sitaxentan—Dyspepsia—Prednisone—atopic dermatitis	6.07e-05	0.00017	CcSEcCtD
Sitaxentan—Decreased appetite—Prednisone—atopic dermatitis	5.99e-05	0.000168	CcSEcCtD
Sitaxentan—Rash—Prednisolone—atopic dermatitis	5.98e-05	0.000167	CcSEcCtD
Sitaxentan—Dermatitis—Prednisolone—atopic dermatitis	5.97e-05	0.000167	CcSEcCtD
Sitaxentan—Diarrhoea—Methylprednisolone—atopic dermatitis	5.95e-05	0.000167	CcSEcCtD
Sitaxentan—Fatigue—Prednisone—atopic dermatitis	5.94e-05	0.000166	CcSEcCtD
Sitaxentan—Headache—Prednisolone—atopic dermatitis	5.94e-05	0.000166	CcSEcCtD
Sitaxentan—Constipation—Prednisone—atopic dermatitis	5.89e-05	0.000165	CcSEcCtD
Sitaxentan—Vomiting—Hydrocortisone—atopic dermatitis	5.89e-05	0.000165	CcSEcCtD
Sitaxentan—Rash—Hydrocortisone—atopic dermatitis	5.84e-05	0.000163	CcSEcCtD
Sitaxentan—Dermatitis—Hydrocortisone—atopic dermatitis	5.84e-05	0.000163	CcSEcCtD
Sitaxentan—Headache—Hydrocortisone—atopic dermatitis	5.8e-05	0.000162	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—NGF—atopic dermatitis	5.79e-05	0.000744	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL8—atopic dermatitis	5.77e-05	0.00074	CbGpPWpGaD
Sitaxentan—Dizziness—Triamcinolone—atopic dermatitis	5.77e-05	0.000161	CcSEcCtD
Sitaxentan—Dizziness—Methylprednisolone—atopic dermatitis	5.75e-05	0.000161	CcSEcCtD
Sitaxentan—Feeling abnormal—Prednisone—atopic dermatitis	5.68e-05	0.000159	CcSEcCtD
Sitaxentan—Asthenia—Betamethasone—atopic dermatitis	5.68e-05	0.000159	CcSEcCtD
Sitaxentan—Asthenia—Dexamethasone—atopic dermatitis	5.68e-05	0.000159	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCR5—atopic dermatitis	5.64e-05	0.000723	CbGpPWpGaD
Sitaxentan—Nausea—Prednisolone—atopic dermatitis	5.63e-05	0.000158	CcSEcCtD
Sitaxentan—Vomiting—Triamcinolone—atopic dermatitis	5.55e-05	0.000155	CcSEcCtD
Sitaxentan—Vomiting—Methylprednisolone—atopic dermatitis	5.53e-05	0.000155	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—IL2—atopic dermatitis	5.51e-05	0.000708	CbGpPWpGaD
Sitaxentan—Nausea—Hydrocortisone—atopic dermatitis	5.5e-05	0.000154	CcSEcCtD
Sitaxentan—Rash—Triamcinolone—atopic dermatitis	5.5e-05	0.000154	CcSEcCtD
Sitaxentan—Dermatitis—Triamcinolone—atopic dermatitis	5.49e-05	0.000154	CcSEcCtD
Sitaxentan—Rash—Methylprednisolone—atopic dermatitis	5.49e-05	0.000154	CcSEcCtD
Sitaxentan—Dermatitis—Methylprednisolone—atopic dermatitis	5.48e-05	0.000153	CcSEcCtD
Sitaxentan—Urticaria—Prednisone—atopic dermatitis	5.48e-05	0.000153	CcSEcCtD
Sitaxentan—Headache—Triamcinolone—atopic dermatitis	5.46e-05	0.000153	CcSEcCtD
Sitaxentan—Headache—Methylprednisolone—atopic dermatitis	5.45e-05	0.000153	CcSEcCtD
Sitaxentan—Body temperature increased—Prednisone—atopic dermatitis	5.45e-05	0.000153	CcSEcCtD
Sitaxentan—Diarrhoea—Betamethasone—atopic dermatitis	5.41e-05	0.000152	CcSEcCtD
Sitaxentan—Diarrhoea—Dexamethasone—atopic dermatitis	5.41e-05	0.000152	CcSEcCtD
Sitaxentan—Dizziness—Betamethasone—atopic dermatitis	5.23e-05	0.000146	CcSEcCtD
Sitaxentan—Dizziness—Dexamethasone—atopic dermatitis	5.23e-05	0.000146	CcSEcCtD
Sitaxentan—Nausea—Triamcinolone—atopic dermatitis	5.18e-05	0.000145	CcSEcCtD
Sitaxentan—Nausea—Methylprednisolone—atopic dermatitis	5.17e-05	0.000145	CcSEcCtD
Sitaxentan—Hypersensitivity—Prednisone—atopic dermatitis	5.08e-05	0.000142	CcSEcCtD
Sitaxentan—Vomiting—Dexamethasone—atopic dermatitis	5.03e-05	0.000141	CcSEcCtD
Sitaxentan—Vomiting—Betamethasone—atopic dermatitis	5.03e-05	0.000141	CcSEcCtD
Sitaxentan—Rash—Betamethasone—atopic dermatitis	4.99e-05	0.00014	CcSEcCtD
Sitaxentan—Rash—Dexamethasone—atopic dermatitis	4.99e-05	0.00014	CcSEcCtD
Sitaxentan—Dermatitis—Dexamethasone—atopic dermatitis	4.99e-05	0.00014	CcSEcCtD
Sitaxentan—Dermatitis—Betamethasone—atopic dermatitis	4.99e-05	0.00014	CcSEcCtD
Sitaxentan—Headache—Betamethasone—atopic dermatitis	4.96e-05	0.000139	CcSEcCtD
Sitaxentan—Headache—Dexamethasone—atopic dermatitis	4.96e-05	0.000139	CcSEcCtD
Sitaxentan—Asthenia—Prednisone—atopic dermatitis	4.94e-05	0.000138	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—NFKBIA—atopic dermatitis	4.78e-05	0.000613	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL8—atopic dermatitis	4.76e-05	0.000611	CbGpPWpGaD
Sitaxentan—Diarrhoea—Prednisone—atopic dermatitis	4.72e-05	0.000132	CcSEcCtD
Sitaxentan—Nausea—Betamethasone—atopic dermatitis	4.7e-05	0.000132	CcSEcCtD
Sitaxentan—Nausea—Dexamethasone—atopic dermatitis	4.7e-05	0.000132	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—GLB1—atopic dermatitis	4.7e-05	0.000603	CbGpPWpGaD
Sitaxentan—Dizziness—Prednisone—atopic dermatitis	4.56e-05	0.000128	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—IL2—atopic dermatitis	4.55e-05	0.000584	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—atopic dermatitis	4.53e-05	0.000581	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ADSL—atopic dermatitis	4.5e-05	0.000578	CbGpPWpGaD
Sitaxentan—Vomiting—Prednisone—atopic dermatitis	4.38e-05	0.000123	CcSEcCtD
Sitaxentan—Rash—Prednisone—atopic dermatitis	4.35e-05	0.000122	CcSEcCtD
Sitaxentan—Dermatitis—Prednisone—atopic dermatitis	4.34e-05	0.000122	CcSEcCtD
Sitaxentan—Headache—Prednisone—atopic dermatitis	4.32e-05	0.000121	CcSEcCtD
Sitaxentan—CYP2C9—Metabolism—GLB1—atopic dermatitis	4.28e-05	0.00055	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK8—atopic dermatitis	4.19e-05	0.000538	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ADSL—atopic dermatitis	4.11e-05	0.000527	CbGpPWpGaD
Sitaxentan—Nausea—Prednisone—atopic dermatitis	4.09e-05	0.000115	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	3.42e-05	0.000439	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL8—atopic dermatitis	3.41e-05	0.000437	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—atopic dermatitis	3.26e-05	0.000418	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—atopic dermatitis	3.24e-05	0.000416	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	3.12e-05	0.000401	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK8—atopic dermatitis	3e-05	0.000385	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GLB1—atopic dermatitis	2.83e-05	0.000363	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ADSL—atopic dermatitis	2.71e-05	0.000348	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—atopic dermatitis	2.67e-05	0.000343	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—atopic dermatitis	1.91e-05	0.000246	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPARA—atopic dermatitis	1.52e-05	0.000196	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPARA—atopic dermatitis	1.39e-05	0.000178	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPARA—atopic dermatitis	9.17e-06	0.000118	CbGpPWpGaD
